Therapy of alopecia areata: On the cusp and in the future

Journal of Investigative Dermatology Symposium Proceedings

Volumn 8, Issue 2, 2003, Pages 207-211

  Price, Vera H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic therapies; Immunomodulating drugs; Langerhans cells; Lymphocytes; Macrophages

Indexed keywords

ALEFACEPT; ANTINUCLEAR ANTIBODY; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; PIMECROLIMUS; PSORBAN; TACROLIMUS; UNCLASSIFIED DRUG;

ALOPECIA AREATA; CLINICAL TRIAL; CONFERENCE PAPER; CREAM; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG INTOXICATION; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; IMMUNOMODULATION; KIDNEY INJURY; LIVER INJURY; LYMPHOMA; MULTIPLE SCLEROSIS; PANCYTOPENIA; SIDE EFFECT; TUBERCULOSIS;

EID: 0141595201     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1087-0024.2003.00811.x     Document Type: Conference Paper

References (40)

1. Abrams JR, Lebwohl MG, Guzzo CA, et al: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243-1252, 1999
2. Asadullah K, Docke WD, Ebeling M, et al: Interleukin 10 treatment of psoriasis: Clinical results of a phase 11 trial. Arch Dermatol 135:187-192, 1999
3. Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud L, Brousse N, Prost Y: Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 114:112-116, 2000
4. Carroll JM, McElwee KJ, King LE, Byrne MC, Sundberg JP: Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 119:392-402, 2002
5. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 357:1842-1847, 2001
6. Colombe BW, Lou CD, Price VH: The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Invest Dermatol Symp Proc The 4:216-219, 1999
7. Eichenfield LF, Lucky AW, Boguniewicz M, et al: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46:495-504, 2002
8. Feldmann KA, Kunte C, Wollenberg A, Wolfe H: Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 147:1031-1032, 2002
9. Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R, McElwee KJ: Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 7:213-230, 2001
10. Ghoreschi K, Thomas P, Breit S, et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9:40-46, 2003
11. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS: Mediation of alopecia areata by cooperation between CD4 + and CD8+ T lymphocytes: Transfer to human scalp explants on Prkdc (scid) mice. Arch Dermatol 138:916-922, 2002
12. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS: Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc (scid) mice. J Invest Dermatol 117:1357-1362, 2001
13. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS: Antoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 101:62-67, 1998
14. Gottlieb AB: Etanercept for psoriasis and psoriatic arthritis. In: Gottlieb AB, Weinstein GD (eds). Therapy of Moderate-to-Severe Psoriasis, 2nd edn. New York: Marcel Dekker, Inc. 2003; 261-285
15. Gottlieb AB: Infliximab for psoriasis. In: Gottlieb AB, Weinstein GD, ed. Therapy of Moderate-to-Severe Psoriasis, 2nd edn. New York: Marcel Dekker, Inc. 2003; 307-331
16. Gottlieb AB, Miller B, Lowe N, et al: Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of severe plaque psoriasis. J Cutan Med Surg, in Press
17. Gupta AK, Ellis CN, Cooper KD, et al: Oral cyclosporine for the treatment of alopecia areata. J Am Acad Dermatol 22:242-250, 1990
18. Hoffmann T: The potential role of cytokines and T cells in alopecia areata. J Invest Dermatol Symp Proc The 4:235-238, 1999
19. Hoffmann R, Wenzel E, Huth A, van der Steen P, Schaufele M, Henninger H, Happle R: Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 103:530-533, 1994
20. Khoury EL, Price VH, Abdel-Salam MM, Stern M, Greenspan JS: Topical minoxidilin alopecia areata. No effect on the perifollicular lymphoid infiltration. J Invest Dermatol 99:40-47, 1992
21. Kimball AB, Kawamura T, Tejura K, et al: Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 138:1341-1346, 2002
22. Kirby B, Griffiths CE: Novel immune-bascd therapies for psoriasis. Br J Dermatol 146:546-551, 2002
23. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1-23, 2002
24. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821-833, 2002
25. Lawrence ID: Tacrolimus (FK506): Experience in dermatology. Dermatologic Ther 5:74-84, 1998
26. McElwee KJ, Spiers EM, Oliver RF: In vivo depletion of CD8+ T Cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 135:211-217, 1996
27. McElwee KJ, Spiers EM, Oliver RF: Partial restoration of hair growth in the DEBR model for alopecia areata after in vivo depletion of CD4 + T cells. Br J Dermatol 140:432-437, 1999
28. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 356:385-390, 2000
29. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568-576, 1997
30. Papp K, Bissonnette R, Krueger JG, et al: The treatment of moderate to severe psoriasis with a new and-CD11a monoclonal antibody. J Am Acad Dermatol 45:665-674, 2001
31. Price VH: Treatment of hair loss. N Engl J Med 341:964-973, 1999
32. Price VH, Colombe BW: Heritable factors distinguish two types of alopecia areata. Dermatol Clin 14:679-689, 1996
33. Rothbard JB, Garlington S, Lin Q, et al: Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6:1253-1257, 2000
34. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III: Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through, 1989. Mayo Clin Proc The 70:628-633, 1995
35. Schneider LC: New treatment for atopic dermatitis. Immunol Allergy Clinics North America 22:141-152, 2002
36. Singri P, West DP, Gordon KB: Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 138:657-663, 2002
37. Thiers BH: Topical tacrolimus: Treatment failure in a patient with alopecia areata. Arch Dermatol 136:124, 2000
38. Todes-Taylor N, Turner R, Wood GS, Stratte PT, Morhenn VB: T cell subpopulations in alopecia areata. J Am Acad Dermatol 11:216-223, 1984
39. Welsh EA, Clark HA, Epstein SZ, et al: Human leukocyte antigen - DQB1*03 alleles are associated with alopecia areata. J Invest Dermatol 103:758, 1994
40. Wiseman MC, Shapiro J, MacDonald N, Lui H: Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 137:063-1068, 2001